Article · 21 Jul 2026
Case reportPublished 2017
Nivolumab-Induced Rapid Tumor Remission of Pulmonary Adenocarcinoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. Nivolumab received FDA approval for the treatment of melanoma in December 2014. On 24 April 2015, the Committee for Medical Products for Human Use of the European Medicine Agency recommended approval of Nivolumab for metastatic melanoma as a monotherapy. In March 2015, the US FDA approved it for the treatment of squamous non-small cell lung cancer. This case reports about a patient with metastatical pulmonary adenocarcinoma who benefited from the therapy with nivolumab. Already after 10 weeks of treatment with nivolumab, we registered rapid tumor remission.
Keywords
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Oncology & Cancer Case Reports.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalOncology & Cancer Case Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Falkenstern-Ge RF”
- BylineArticles whose byline prints “Kimmich M”
- BylineArticles whose byline prints “Wohlleber M”
- BylineArticles whose byline prints “Bode-Erdmann S”
- BylineArticles whose byline prints “Friedel G”
- BylineArticles whose byline prints “Ott G”
- BylineArticles whose byline prints “Kohlhäufl M”